Cancer Research Cell Death Mechanisms and Cancer Therapy Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nepomuceno, R. R.
Right arrow Articles by Martinez, O. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nepomuceno, R. R.
Right arrow Articles by Martinez, O. M.
[Cancer Research 63, 4472-4480, August 1, 2003]
© 2003 American Association for Cancer Research

Immunology

Rapamycin Inhibits the Interleukin 10 Signal Transduction Pathway and the Growth of Epstein Barr Virus B-cell Lymphomas1

Ronald R. Nepomuceno, Cynthia E. Balatoni, Yaso Natkunam, Andrew L. Snow, Sheri M. Krams and Olivia M. Martinez2

Departments of Surgery, [R. R. N., C. E. B., S. M. K., O. M. M.] and Pathology, [Y. N.] and Program in Immunology, [A. L. S., S. M. K., O. M. M.], Stanford University School of Medicine, Stanford, California 94305

EBV-infected B-cell lymphomas are a potentially life-threatening complication in bone marrow and solid organ transplant recipients. Immunosuppressive drugs required to prevent allograft rejection also impair anti-EBV T-cell immunity, thereby increasing the risk of EBV-associated disease. Here we demonstrate that the immunosuppressant rapamycin (RAPA) has a strong antiproliferative effect in vitro on B-cell lines derived from organ transplant recipients with EBV-associated posttransplant lymphoproliferative disorder (PTLD). Furthermore, RAPA significantly inhibits or delays the growth of solid tumors established from EBV-infected B-cell lines in a xenogeneic mouse model of PTLD. RAPA acts via cell cycle arrest, induction of apoptosis, and, most importantly, inhibition of interleukin 10 secretion, a necessary autocrine growth factor. The reduced interleukin 10 production is accompanied by corresponding decreases in the constitutive activation of the growth-promoting transcription factors signal transducer and activator of transcription 1 and 3. Thus, RAPA can limit B-cell lymphoma growth while simultaneously providing immunosuppression to prevent graft rejection in patients who are otherwise at risk for EBV-associated PTLD. Moreover, these findings may have application to other EBV-associated malignancies.




This article has been cited by other articles:


Home page
 Ann OncolHome page
J. I. Cohen, H. Kimura, S. Nakamura, Y.-H. Ko, and E. S. Jaffe
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
Ann. Onc., September 1, 2009; 20(9): 1472 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. L. Lambert and O. M. Martinez
Latent Membrane Protein 1 of EBV Activates Phosphatidylinositol 3-Kinase to Induce Production of IL-10
J. Immunol., December 15, 2007; 179(12): 8225 - 8234.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Maecker, T. Jack, M. Zimmermann, H. Abdul-Khaliq, M. Burdelski, A. Fuchs, P. Hoyer, S. Koepf, U. Kraemer, G. F. Laube, et al.
CNS or Bone Marrow Involvement As Risk Factors for Poor Survival in Post-Transplantation Lymphoproliferative Disorders in Children After Solid Organ Transplantation
J. Clin. Oncol., November 1, 2007; 25(31): 4902 - 4908.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
K. S. Gotze, D. Hoffmann, H. M. Schatzl, C. Peschel, F. Fend, and T. Decker
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia
Haematologica, September 1, 2007; 92(9): 1282 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Pascual
Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors
Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i27 - i35.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S.-H. Sin, D. Roy, L. Wang, M. R. Staudt, F. D. Fakhari, D. D. Patel, D. Henry, W. J. Harrington Jr, B. A. Damania, and D. P. Dittmer
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
Blood, March 1, 2007; 109(5): 2165 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. K. Hong, M. L. Gulley, W.-H. Feng, H.-J. Delecluse, E. Holley-Guthrie, and S. C. Kenney
Epstein-Barr Virus Lytic Infection Contributes to Lymphoproliferative Disease in a SCID Mouse Model
J. Virol., November 15, 2005; 79(22): 13993 - 14003.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. M. Ghobrial, T. M. Habermann, M. J. Maurer, S. M. Geyer, K. M. Ristow, T. S. Larson, R. C. Walker, S. M. Ansell, W. R. Macon, G. G. Gores, et al.
Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders
J. Clin. Oncol., October 20, 2005; 23(30): 7574 - 7582.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Nefedova, S. Nagaraj, A. Rosenbauer, C. Muro-Cacho, S. M. Sebti, and D. I. Gabrilovich
Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway
Cancer Res., October 15, 2005; 65(20): 9525 - 9535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Wlodarski, M. Kasprzycka, X. Liu, M. Marzec, E. S. Robertson, A. Slupianek, and M. A. Wasik
Activation of Mammalian Target of Rapamycin in Transformed B Lymphocytes Is Nutrient Dependent but Independent of Akt, Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase, Insulin Growth Factor-I, and Serum
Cancer Res., September 1, 2005; 65(17): 7800 - 7808.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T. Schachner, A. Oberhuber, Y. Zou, A. Tzankov, H. Ott, G. Laufer, and J. Bonatti
Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts
Eur. J. Cardiothorac. Surg., February 1, 2005; 27(2): 302 - 306.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood, December 15, 2004; 104(13): 4188 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.